ALNYALNYLAM PHARMACEUTICALS, INC.
Health Care
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest revised up 17.4% for Q3 2025
This is the 7th largest revision in ALNY's history.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest·Q3 2025
Major restatement$280.6M▲ 17.4%
was$239M
Revised up in a 10-Q.
No amendment filed
As reported · Oct 30, 202510-Q · Oct 29, 2026us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestVerify against SEC filingsShow
As reported$239M
Accepted 2025-10-300001628280-25-047345
Restated$280.6M
Accepted 2026-10-290001178670-26-000076
PretaxIncome · reported 2 times · point-in-time, survivorship-free. Every figure traces to its filing above.
Track this the moment it happens
Get a signal the next time ALNY — or any company on your watchlist — restates a number. Every signal lands with the diff and its source filing.